Tian An Medicare Limited (0383) Fair Value & Analysis
Healthcare · HK · Market cap HK$859M
Fair value as of: Aug 2, 2026
From 8 valuation models · updated 8 days ago
Share price −4.7% over the past month.
Below-average quality, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- A fairly wide model range (HK$0.5200 to HK$0.9700) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 2, 2026.
How to read this chart
60‑month range HK$0.6229 – HK$4.71 · fair‑value band HK$0.5200 – HK$0.9700 · the HK$0.8100 price screens above the HK$0.7400 fair value. Dashed = 300-day average. As of Aug 2, 2026.
Analysis
Tian An Medicare Limited (0383) currently trades at HK$0.8100, while our model-based Fair Value estimate is HK$0.7400, implying the stock looks roughly 8.6% fairly valued today. The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Tian An Medicare Limited generated revenue of HK$1.6B at a net margin of -1.6%. Revenue grew 6.1% year over year. It earns a return on equity of -1.1%. Net debt stands at HK$149M. Fundamentals as of Aug 2, 2026
Our scenario range runs from HK$0.5200 (bear case) to HK$0.9700 (bull case); at HK$0.8100, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 40% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -9%, 0383 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 8 models by family
Widest divergence: Multiples (HK$1.20) versus Dividend Discount (HK$0.2900). Highest evidence: ROIC Compounder (72).
Notify me when 0383 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 2, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 35 · Market factors (momentum, volatility) 34
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Tian An Medicare Limited, an investment holding company, primarily operates hospitals in the People's Republic of China and Hong Kong. It operates through Healthcare, Eldercare, Property Development, Property Investment, Financial Services, and Securities Trading and Investments segments.
Full company description
Tian An Medicare Limited, an investment holding company, primarily operates hospitals in the People's Republic of China and Hong Kong. It operates through Healthcare, Eldercare, Property Development, Property Investment, Financial Services, and Securities Trading and Investments segments. The company is also involved in property development of independent living units and project management of health campus with a focus on eldercare and retirement community including elderly nursing home, service apartments, independent living units and commercial area comprising shopping mall, retail shops, and club hall facilities. In addition, it develops and sells properties and lands; leases properties; and provides loan financial and healthcare services, as well as trading of securities listed in overseas exchange. The company was formerly known as China Medical & HealthCare Group Limited and changed its name to Tian An Medicare Limited in April 2024. Tian An Medicare Limited was incorporated in 1989 and is based in Wan Chai, Hong Kong. The company operates as a subsidiary of Tian An China Investments Company Limited.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Tian An Medicare Limited reported revenue of HK$1.6B in FY2026 versus HK$1.5B in FY2022, a compound +2.9%/yr. Reported net income was −HK$26.8M in FY2026.
of which total revenue +14.2 pp · buybacks/dilution +21.3 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch 0383: get an alert when its fair value changes →
Peer Group
Medical Care Facilities · 261 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 2, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare Tian An Medicare Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Tian An Medicare Limited (0383) overvalued or undervalued?
What is the fair value of 0383?
What is the quality score of 0383?
What is the revenue of Tian An Medicare Limited (0383)?
What is the net profit margin of 0383?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Tian An Medicare Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.